Welcome to our dedicated page for IMMUTEP SEC filings (Ticker: IMMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IMMUTEP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IMMUTEP's regulatory disclosures and financial reporting.
Immutep Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish an exhibit describing a new research collaboration. The exhibit, titled “Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti,” indicates that the company and the George Washington University Cancer Center plan to evaluate neoadjuvant Efti in a cancer setting. This Form 6-K serves as the formal vehicle to provide that collaboration announcement to investors and regulators.